^
    8ms
    The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=67, Completed, Curacle Co., Ltd. | Active, not recruiting --> Completed | Phase classification: P2a --> P2 | Trial completion date: Mar 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> May 2023
    Trial completion • Phase classification • Trial completion date • Trial primary completion date
    |
    CU06
    11ms
    CU06-1004 alleviates oxidative stress and inflammation on folic acid-induced acute kidney injury in mice. (PubMed, J Pharmacol Sci)
    These findings suggest CU06-1004 as a potential therapeutic agent for folic acid-induced AKI.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • KIM1 (Kidney injury molecule 1) • LCN2 (Lipocalin-2)
    |
    CU06
    over1year
    CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome. (PubMed, Front Pharmacol)
    Notably, the HDIL-2 and CU06-1004 combination therapy considerably reduced tumor growth in the B16F10 melanoma mouse model. Our data suggest that CU06-1004 acts as a potential anticancer drug candidate, not only by preventing HDIL-2-induced VLS but also by enhancing the anticancer effects of HDIL-2 immunotherapy.
    Journal
    |
    CU06